Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Malvern Signs Exclusive Agreement with Affinity Biosensors

Published: Tuesday, March 05, 2013
Last Updated: Tuesday, March 05, 2013
Bookmark and Share
Agreement to distribute Affinity Biosensors’ Archimedes system extends Malvern Instruments’ biopharma solutions.

Malvern Instruments Ltd. (Malvern, UK) has signed an exclusive distribution agreement with Affinity Biosensors LLC (Santa Barbara, CA, USA) which will extend the range of solutions that Malvern offers to the biopharmaceutical sector.

The distribution agreement covers all geographies outside the USA and Canada.

Under the terms of the agreement Malvern will distribute the Archimedes Particle Metrology system, developed and manufactured by Affinity Biosensors, through its subsidiaries in Europe and Asia.

Malvern will establish a co-marketing arrangement with Affinity Biosensors in North America.

Archimedes, which won the Pittcon Editors Gold Award in 2010 and an R&D100 Award in 2010, employs a unique patented technology co-invented by the Massachusetts Institute of Technology (MIT) and Affinity Biosensors.

Using the technique of Resonant Mass Measurement (RMM), Archimedes detects and counts particles and determines their mass and size with high resolution and accuracy, in small sample volumes.

A key area of application is the measurement of protein aggregation in biotherapeutic formulations, which provides critical information needed to speed development and improve drug safety and efficacy.

Archimedes provides the technology to both count and characterize aggregates, making it invaluable to biopharmaceutical manufacturers and developers.

“We are very pleased to be involved with this exciting new technology and to be adding it to our growing range of solutions for biopharmaceutical researchers,” said Duncan Roberts, Business Development Director for Malvern.

Roberts continued, “Protein aggregation is a significant challenge in the development of protein-based drugs, and an area of increasing interest and potential regulation. Archimedes will sit alongside Malvern’s Zetasizer and Viscotek systems, all of which deliver complementary solutions for customers in this fast growing pharmaceutical industry sector.”

Affinity Biosensors’ CEO Ken Babcock commented, “Archimedes has been adopted at many leading US biopharmaceutical companies. Our partnership with Malvern will extend Archimedes’ reach worldwide, and we are glad to see it alongside Malvern’s leading materials characterization technology. Archimedes users are sure to benefit from Malvern’s world-class support and applications expertise.”

Archimedes allows precise measurement of size and mass of particles with diameters down to 50nm.

Measurements are unaffected by optical or shape variations, and gentle fluidics ensure that fragile aggregates are not disrupted.

The instrument can measure high viscosity samples and consumes as little as 100µl of precious protein formulation. Archimedes can accept particle concentrations up to 1x109 per ml, allowing direct study of undiluted high concentration formulations.

Archimedes can also differentiate between protein aggregates and silicone oil droplets in an injectable biopharmaceutical using buoyant mass measurement, something that no other technology can do at the submicron size scale.

Details of Malvern’s rapidly expanding range of protein characterization solutions are available at, with full descriptions and specifications for the new Archimedes systems at

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Malvern Specialist Discusses Light Scattering Techniques at BioProcess International Europe 2011
Dr Hanna Jankevics will present a poster at the 7th annual BioProcess International Europe conference in Nice (France).
Thursday, April 14, 2011
Malvern Specialist Tests Sensitivity Limits of Dynamic Light Scattering
Malvern’s Zetasizer Nano systems use light scattering techniques to measure the hydrodynamic size, zeta potential and molecular weight of proteins and nanoparticles.
Wednesday, October 06, 2010
Scientific News
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Novel Proteins Linked to Huntington's Disease
University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos